Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an ... compared to a 0.1% drop in the placebo group. The result caused the trial to meet its primary endpoint.

One study found that common adverse effects were mild to moderate for both tirzepatide and semaglutide. This study also found ...

The resolution of steatohepatitis without worsening of fibrosis was achieved in 62.9% of participants in the semaglutide group compared to 34.3% in the placebo group (difference: 28.7 percentage ...

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

While in the US, EU, Japan and some other countries semaglutide has IP protection until 2028-2031, other significant markets have no such restrictions and patents start expiring as early as 2026.